<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01491360</url>
  </required_header>
  <id_info>
    <org_study_id>AVG-2013-01</org_study_id>
    <nct_id>NCT01491360</nct_id>
  </id_info>
  <brief_title>LaserACE® Procedure Restore Visual Function and Range of Accommodation LaserACE® Procedure</brief_title>
  <official_title>Evaluation of the Safety &amp; Efficacy of the LaserACE® Procedure to Restore Visual Function and Range of Accommodation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ACE Vision Group, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vision Renu Taiwan Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ACE Vision Group, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A new minimally invasive procedure for treating presbyopia is being evaluated to determine if&#xD;
      there is improvement in near and intermediate vision after treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of subjects with binocular near visual acuity of 20/32 (logMAR 0.20) or better at six months postoperatively with distance correction in place measured at 40cm and 60cm.</measure>
    <time_frame>6 months</time_frame>
    <description>binocular near visual acuity of 20/32 (logMAR 0.20) or better at six months postoperatively with distance correction in place measured at 40cm and 60cm.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Presbyopia</condition>
  <arm_group>
    <arm_group_label>LaserACE(R) procedure performed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The LaserACE(R) procedure (partial depth scleral micro-excisions with an Er:YAG laser in a specified pattern) will be performed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>LaserACE(R)</intervention_name>
    <description>Partial depth scleral micro-excisions with an Er:YAG laser in a predetermined pattern.</description>
    <arm_group_label>LaserACE(R) procedure performed</arm_group_label>
    <other_name>LaserACE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Willing and able to understand and sign an informed consent;&#xD;
&#xD;
          2. Willing and able to attend postoperative examinations per protocol schedule;&#xD;
&#xD;
          3. 40 years of age or greater, of either gender or any race;&#xD;
&#xD;
          4. Less than (&lt;) 1.00D of astigmatism in each eye, measured in their manifest refraction;&#xD;
&#xD;
          5. Mean refractive spherical equivalent refraction (MRSE) of +/- 0.50D for distance&#xD;
             vision; Note: Subjects who meet this criterion as a result of prior laser refractive&#xD;
             surgery (LASIK, LASEK or PRK) may qualify; however, the subject must have had the LVC&#xD;
             procedure performed at least 12 months prior to the LaserACE® procedure and be stable.&#xD;
&#xD;
          6. Uncorrected distance visual acuity (UDVA) is better than or equal to 20/40 (logMAR&#xD;
             0.30) in each eye, and a Corrected Distance Visual Acuity (CDVA) is better than or&#xD;
             equal to 20/32 (logMAR 0.20) in each eye;&#xD;
&#xD;
          7. Demonstrate Stereopsis of 200 seconds of arc or better using a Randot stereoscopic fly&#xD;
             test and reading correction;&#xD;
&#xD;
          8. In good ocular health with the exception of presbyopia;&#xD;
&#xD;
          9. Presbyopia as demonstrated by:&#xD;
&#xD;
               1. Currently wearing reading glasses and/or bifocals with an ADD of +1.50D or more;&#xD;
                  and&#xD;
&#xD;
               2. Reduced near visual acuity when corrected for distance (DCNVA of 20/50 (logMAR&#xD;
                  0.40) or worse; and&#xD;
&#xD;
               3. Amplitude of accommodation (AA) of 1.50D or less as measured by the minus lens&#xD;
                  test; OR&#xD;
&#xD;
               4. Amplitude of accommodation (AA) of 1.50D or less as measured by the iTrace&#xD;
                  aberrometer.&#xD;
&#xD;
         10. Intraocular pressure (IOP) &gt;11mmHg and &lt; 30 mmHg in each eye without IOP-lowering&#xD;
             medication;&#xD;
&#xD;
         11. Less than or equal to (≤) 0.50D difference between the manifest refraction and the&#xD;
             cycloplegic refraction;&#xD;
&#xD;
         12. Stable distance refraction is present, defined as ≤ 0.50D variation of refraction in&#xD;
             the 12 months prior to the LaserACE® procedure. Manifest refraction cannot vary more&#xD;
             than 0.50D from current spectacles that are at least 12 months of age, or from a&#xD;
             documented refraction at least 12 months prior to the preoperative baseline exam;&#xD;
&#xD;
         13. Completed a washout period of two weeks (14 days) prior to LaserACE® procedure from&#xD;
             prior treatment with:&#xD;
&#xD;
               -  NSAIDS, blood thinners, aspirin, and other substances which may increase&#xD;
                  bleeding;&#xD;
&#xD;
               -  Any anti-oxidant supplements (e.g., Vitamin B6, Vitamin B12, Vitamin E, Vitamin&#xD;
                  C, Acai, Ocuvite, etc);&#xD;
&#xD;
               -  Anti-oxidant food supplements, such as shitake mushroom, mushroom extract and&#xD;
                  oral anti-oxidants.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Self-reported current pregnancy or breast-feeding, or plans to become pregnant during&#xD;
             the entire study period;&#xD;
&#xD;
          2. History of ocular trauma or prior ocular surgery, or expected to require retinal laser&#xD;
             treatment or other ocular surgical intervention;&#xD;
&#xD;
          3. Presence of ocular pathology other than cataract such as:&#xD;
&#xD;
               -  Amblyopia or strabismus&#xD;
&#xD;
               -  Corneal abnormalities or disease&#xD;
&#xD;
               -  Dry Eye (International Task Force Level 3 or greater)&#xD;
&#xD;
               -  Pupil abnormalities (e.g., corectopia, Adie's)&#xD;
&#xD;
               -  Capsule or zonnular abnormalities&#xD;
&#xD;
               -  Intraocular inflammation&#xD;
&#xD;
               -  Retinal disease or pathology&#xD;
&#xD;
               -  Glaucoma (any type)&#xD;
&#xD;
               -  History of prior ocular surgery other than keratorefractive surgery;&#xD;
&#xD;
          4. Known pathology that may affect visual acuity and/or are predicted to cause future&#xD;
             acuity losses to a level of 20/30 (logMAR 0.18) or worse (e.g., macular degeneration);&#xD;
&#xD;
          5. Previous radial keratotomy or other corneal surgery (e.g., corneal transplant,&#xD;
             DSAEK/DSEK, lamellar keratoplasty), except for LASIK, EpiLASIK/LASEK, or PRK;&#xD;
&#xD;
          6. Previous anterior or posterior chamber surgery (e.g., vitrectomy, laser iridotomy);&#xD;
&#xD;
          7. Keratoconus or keratoconus suspect with CDVA of less than (&lt;) 20/20 (&lt; logMAR 0.00) at&#xD;
             distance;&#xD;
&#xD;
          8. Near visual acuity at 40cm equivalent to their distance vision with distance&#xD;
             correction (i.e., no evident effect of reduced accommodative range);&#xD;
&#xD;
          9. Use of systemic or ocular medications that may affect vision (the use of any miotic or&#xD;
             cycloplegic agent is specifically contraindicated);&#xD;
&#xD;
         10. Acute or chronic disease or illness that could increase the operative risk or confound&#xD;
             the study outcome(s) (e.g., diabetes mellitus, immunocompromised, connective tissue&#xD;
             disease);&#xD;
&#xD;
         11. Uncontrolled systemic or ocular disease;&#xD;
&#xD;
         12. Any abnormality preventing reliable applanation tonometry in EITHER eye;&#xD;
&#xD;
         13. Undilatable pupil such that one cannot examine the periphery of the retina;&#xD;
&#xD;
         14. Functional eye preference, defined as phoria measuring over 15dp horizontally and/or&#xD;
             over 2dp vertically, any strabismus, or suppression.&#xD;
&#xD;
         15. History of scleral ectasia, scleritis, or episcleritis; or thin sclera &lt; 400 microns,&#xD;
             as determined by taking the average of three measurements with ultrasound&#xD;
             biomicroscopy (UBM) pachymetry;&#xD;
&#xD;
         16. History of nuclear sclerosis LOCS III grade 2 or worse and/or other cataracts reducing&#xD;
             CDVA;&#xD;
&#xD;
         17. Known allergies to study medications including topical steroids, antibiotics and&#xD;
             NSAIDS;&#xD;
&#xD;
         18. Per PI discretion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Ma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gung Memorial Hospital, Taipei, Taiwan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 22, 2011</study_first_submitted>
  <study_first_submitted_qc>December 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2011</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Presbyopia</keyword>
  <keyword>sclera</keyword>
  <keyword>LaserACE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Presbyopia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

